Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations (NCT04603001)
A Phase 1 Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations
🩺 Plain-English Summary (8th-Grade Level)
This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent isocitrate dehydrogenase (IDH) inhibitor, in patients with IDH1 and/or IDH2-mutant advanced hematologic malignancies who may have received standard therapy
Who can join: Review the eligibility criteria below.
Location: City of Hope National Medical Center — Duarte, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (37 Sites)
Showing the first 25 of 37 sites.
- City of Hope National Medical Center — Duarte, California
- UCLA Medical Center — Los Angeles, California
- University of California, Davis - Health Systems — Sacramento, California
- H Lee Moffitt Cancer Center — Tampa, Florida
- Northwestern University — Chicago, Illinois
- University of Chicago Hospital — Chicago, Illinois
- Massachusetts General Hospital — Boston, Massachusetts
- Roswell Park Cancer Institute — Buffalo, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
- Vanderbilt University Medical Center — Nashville, Tennessee
- University of Texas MD Anderson Cancer Center — Houston, Texas
- Peter MacCallum Cancer Centre — Melbourne, Victoria
- The Alfred Hospital — Melbourne, Victoria
- Linear Clinical Research — Nedlands, Western Australia
- Cliniques universitaires Saint-Luc — Brussels,
- BC Cancer Vancouver — Vancouver, British Columbia
- Princess Margaret Hospital — Toronto, Ontario
- Jewish General Hospital — Montreal, Quebec
- Helsinki University Hospital - Comprehensive Cancer Center (HYKS - Syöpäkeskus) — Helsinki,
- Institut Paoli-Calmettes — Marseille,
- Hopital Saint Louis — Paris,
- Centre hospitalier universitaire de Haut Leveque — Pessac,
- Centre Hospitalier Lyon Sud — Pierre-Bénite,
- Institut Claudius Regaud — Toulouse,
📞 Contact the Study Coordinator
Phone: (800) 826-4673
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Acute Myeloid Leukemia (AML)
- A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy — Duarte, California
- A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant — New York, New York
- Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN — Boston, Massachusetts
- A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia — Duarte, California
- Study of Monzosertib In Patients With R/R AML Or High-Risk Myelodysplastic Syndrome — Houston, Texas
Explore by condition: All Acute Myeloid Leukemia (AML) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.